ArticleFrontiers in endocrinology2026
Growth patterns in patients with congenital adrenal hyperplasia analyzed by the QEPS growth model.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Patients with congenital adrenal hyperplasia (CAH) often face challenges in achieving their target adult height. The QEPS growth model, previously used for assessing healthy and pathological growth patterns, has not been applied to individuals with CAH. Objective: To evaluate growth patterns in patients with CAH using the QEPS growth model and to compare their growth characteristics with a healthy reference population. Design: A retrospective longitudinal study analyzing growth data collected from 1986 to 2008. Setting: The study was conducted in a single tertiary care center. Patients: The study included 25 patients (13 girls) with CAH, subtyped into salt wasting (SW; 12 boys, 8 girls) and simple virilizing (SV; 5 girls). Growth data were compared with a healthy reference cohort. Interventions: All patients were treated with hydrocortisone, and patients with CAH-SW received mineralocorticoids. Main outcome measures: Growth patterns were analyzed using the QEPS model, which includes specific early life growth (E-function), basic childhood growth (Q-function), and specific pubertal growth (P-function). Final adult height was compared with the reference population and parental heights. Results: CAH-SW boys and girls were longer at birth, exhibited reduced early-life growth, and had reduced puberty-specific growth (lower Pmax), resulting in shorter adult height (1.7 SDS). CAH-SV girls had earlier pubertal growth onset, also leading to reduced adult height (-1.6 SDS). Both groups showed similar basic childhood growth. Conclusions: Patients with CAH-SW displayed distinct growth patterns, including longer birth length but reduced specific early and pubertal growth, resulting in shorter adult height compared with reference populations and parental heights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.